The pathological role of FTO as an m6A demethylase in cancer was first reported in acute myeloid leukemia, and FTO inhibitor R-2-hydroxyglutarate exerts tumor-suppressive activity by targeting FTO/C-Myc/CEBPA pathway, revealing great clinical value [18]. Here, FTO is linked to cancer.